# Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

> **NCT02495077** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 290 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **BIOLOGICAL:** Infliximab
- **DRUG:** Methylprednisolone
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Tacrolimus
- **BIOLOGICAL:** Thymoglobulin®
- **DRUG:** Acetaminophen
- **DRUG:** Loratadine
- **BIOLOGICAL:** Placebo for Infliximab
- **DRUG:** Prednisone
- **DRUG:** Diphenhydramine

## Key facts

- **NCT ID:** NCT02495077
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-02
- **Primary completion:** 2021-07-23
- **Final completion:** 2021-07-23
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2022-08-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02495077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02495077, "Effects of Inhibiting Early Inflammation in Kidney Transplant Patients". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02495077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*